Dr. Kayluz Frias Boligan is a Research Scientist at Thryv Therapeutics, where she investigates the role of SGK1 and SGK1 inhibition in immune responses across a range of disease contexts. She brings strong expertise in cellular immunology assays and molecular biology, applying this foundation to translational, industry-focused research that supports immunology-driven drug discovery and development.

Dr. Frias Boligan holds a PhD in Immunology from the University of Bern in Switzerland. She completed postdoctoral training in immunohematology at Canadian Blood Services and in immunovirology at Université du Québec à Montréal (UQAM).